In these immunodeficient mice, EpCAM-NIR-PIT resulted in slight tumour growth suppression compared to the control and AbPC intravenous injection-only groups (Figure 2E), but there was no significant improvement in survival (Figure 2F), likely due to the regrowth of residual cancer cells. This evidence concerns the gene EPCAM and cancer.